Certara, Inc. (NASDAQ:CERT) Stock Has Average Price Target of $9.92 According to Analysts

Certara, Inc. (NASDAQ:CERT) has been given a consensus recommendation of “Hold” by the thirteen research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $9.92.

Several analysts have commented on CERT shares. Barclays boosted their price target on shares of Certara from $9.00 to $12.00 and gave the stock an “equal weight” rating in a research note on Friday, November 6th. Weiss Ratings upgraded Certara from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, November 9th. Jefferies Financial Group restated a “hold” rating and set a $12.00 price objective on shares of Certara in a research report on Friday, November 6th. TD Cowen lifted their target price on Certara from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Finally, KeyCorp boosted their target price on Certara from $9.00 to $12.00 and gave the stock an “overweight” rating in a research report on Friday, October 16th.

Institutional Trading of Certara

Several hedge funds have recently modified their holdings of CERT. Integrated Wealth Concepts LLC bought a new position in shares of Certara during the 2nd quarter valued at approximately $39,000. GAMMA Investing LLC increased its position in Certara by 21.2% in the third quarter. GAMMA Investing LLC now owns 9,778 shares of the company’s stock worth $90,000 after purchasing an additional 1,710 shares during the last quarter. NorthRock Partners LLC purchased a new stake in Certara during the second quarter valued at $68,000. State of Wyoming purchased a new stake in Certara during the second quarter valued at $72,000. Finally, Perigon Wealth Management LLC bought a new position in Certara during the second quarter valued at $80,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Price Performance

Shares of Certara stock traded down $0.33 on Friday, hitting $11.57. 2,668,404 shares of the company traded hands, compared to its average volume of 2,723,653. Certara has a 52 week low of $4.45 and a 52 week high of $12.61. The business has a 50-day simple moving average of $9.70 and a 200 day simple moving average of $7.40. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.58 and a current ratio of 2.58. The stock has a market capitalization of $1.76 billion, a P/E ratio of -27.55 and a beta of 1.30.

Certara (NASDAQ:CERT) last posted its earnings results on Thursday, November 5th. The company reported $0.09 earnings per share for the quarter, meeting the consensus estimate of $0.09. The company had revenue of $94.90 million during the quarter, compared to analysts’ expectations of $92.01 million. Certara had a negative net margin of 16.14% and a positive return on equity of 3.36%. Certara’s quarterly revenue was down 9.3% on a year-over-year basis. During the same period last year, the company posted $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.310-0.340 EPS. Research analysts expect that Certara will post 0.21 earnings per share for the current fiscal year.

About Certara

Certara provides software and consulting services that support the development and use of medicines. Its biosimulation tools help pharmaceutical and biotechnology companies model how drugs behave in the body, assess potential treatment outcomes, and inform decisions during drug research and development. The company’s offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial simulation, and drug development analysis. Certara also provides scientific and regulatory consulting, including support for regulatory submissions and strategies that use modeling and simulation to guide development programs.